Beijing Gobroad Hospital

This early-stage study is testing the safety and initial effectiveness of an investigational drug called STR-P004 in adults with autoimmune diseases that have returned or not responded to standard treatments. The study will enroll 39 participants with conditions like lupus and in…

This early-stage study is testing the safety of a new cell therapy called OL-CD19-GDT for adults with severe autoimmune diseases that haven't responded to other treatments. The therapy involves modifying a patient's own immune cells to potentially reset the immune system and redu…

This study is testing whether a different type of cell therapy, called CIK cells, can help children and young adults with a hard-to-treat form of B-cell leukemia. The patients in this trial have already tried CAR-T cell therapy, but it stopped working within six months. Researche…

This early-phase study is testing a therapy called CD19 CAR T-cells in people with severe autoimmune diseases that have not improved with standard treatments. The therapy involves collecting a patient's own immune cells, modifying them to target a specific marker (CD19), and infu…

This study is testing two different CAR-T cell therapy strategies for children and young adults with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatments. One approach uses two types of engineered immune cells (CD19 and CD22 CAR-T) in sequ…

This early-stage trial is testing a type of cell therapy called CAR T-cells in people with severe, treatment-resistant lupus. The study aims to find a safe dose and see if the therapy can help control the disease. It will enroll 18 participants aged 3 to 65 who have not responded…

This early-stage study is testing a new two-part treatment for advanced gastrointestinal cancers that have stopped responding to standard therapies. It combines a personalized cancer vaccine with an infusion of specially trained immune cells, both designed to target the patient's…

This study is testing a new cell therapy called CD19-BCMA CAR-T for people with severe autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy is safe and can help control diseases like lupus affecting the kidneys, systemic sclerosis, an…

This study is testing a new type of personalized immune cell therapy called CD7 CAR T-cells for patients with T-cell blood cancers that have returned or not responded to other treatments. The therapy involves collecting a patient's own immune cells or using donor cells, modifying…

This early-stage trial is testing the safety and finding the right dose of a new type of CAR-T cell therapy called FL-33 for people with acute myeloid leukemia that has come back or hasn't responded to other treatments. The study will enroll up to 27 adults and children to see ho…

This study is testing a new cell therapy, originally developed for cancer, for people with severe autoimmune diseases that haven't responded to standard treatments. It uses modified immune cells (CAR-T) from umbilical cord blood to try to reset the body's faulty immune system. Th…

This study is testing a new type of personalized cell therapy called CD5 CAR-T for people with T-cell cancers that have come back or not responded to other treatments. Doctors will modify a patient's own immune cells (or cells from a donor) to better target and fight the cancer. …

This early-stage study is testing the safety of a new type of personalized cell therapy for patients with multiple myeloma that has returned or stopped responding to other treatments and has spread to other tissues. Doctors will collect and modify a patient's own immune cells to …

This trial is testing a personalized cell therapy called CT041 for people with advanced stomach or gastroesophageal junction cancer. After completing standard first-line treatment, participants will have their own immune cells collected, genetically modified to target their cance…

This early-stage study is testing a new cell-based therapy called BiTE-EV for adults whose B-cell leukemia has returned or not responded to other treatments. The main goals are to check if the treatment is safe and to see if it helps control the cancer. A very small group of part…

This early-stage study is testing the safety of a new type of cell therapy for people with multiple myeloma that has come back or stopped responding to other treatments and has spread outside the bone marrow. Doctors will give patients a one-time infusion of specially engineered …

This early-stage study is testing a new cell therapy called TC-G203 for people with advanced solid tumors that have returned or spread. The main goal is to find the safest dose and see how well the body handles the treatment. It is for patients whose cancer has a specific marker …

This early-stage trial is testing a new two-part cell therapy for children and young adults whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments. The therapy involves giving specially engineered immune cells (CAR-T cells) from a donor, f…

This early-stage study is testing a new treatment called CT1190B CAR-T cell therapy for adults with severe lupus or scleroderma that hasn't responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to potentially fight the disease, …

This study is testing a new type of personalized immune cell therapy, called CD5-CAR T cells, for people with aggressive T-cell blood cancers that have come back or not responded to standard treatments. The main goals are to find a safe and effective dose and to see if the therap…